Utility of the Biomarker CA125 in the Diagnosis of Cellular Rejection in Allogeneic Heart Transplantation
| Autor: | Carmen Aguado, Luis Almenar Bonet, Raquel López-Vilella, Luis Martínez Dolz, Begoña Laiz, Nuria Mancheño Franch, Ignacio Sánchez-Lázaro |
|---|---|
| Rok vydání: | 2021 |
| Předmět: |
Graft Rejection
medicine.medical_specialty medicine.medical_treatment Biopsy Carbohydrates Gastroenterology Interquartile range Internal medicine medicine Humans Clinical significance Retrospective Studies Heart transplantation Transplantation medicine.diagnostic_test business.industry Hematopoietic Stem Cell Transplantation Retrospective cohort study medicine.disease Heart failure Biomarker (medicine) Heart Transplantation Surgery business Biomarkers |
| Zdroj: | Transplantation proceedings. 53(9) |
| ISSN: | 1873-2623 |
| Popis: | BACKGROUND To analyze the relationship of the antigen carbohydrate 125 (CA125) biomarker with the cellular rejection of the heart graft during the first year after transplantation. METHODS Retrospective study of consecutive heart transplant (HTx) patients for 1.5 years. The total number of patients included in the study was 23 with a total of 103 follow-ups. In all patients, CA125 was determined before HTx and determined post-HTx in every follow-up. These were performed during months 1, 2, 4, 6, 9, and 12. Endomyocardial biopsy was performed in all revisions to assess the degree of graft rejection in the pathologic study. The biopsy results were grouped into 1. absence of rejection and 2. presence of some degree of rejection. RESULTS The mean pretransplant CA125 value presented a median of 120 U/mL with an interquartile range of 28.8 U/mL. One month after transplantation, the value was reduced by 20% and at 2 months by 81%. In subsequent reviews, plasma values were always between 10 and 20 U/mL. When comparing the values by periods and according to the presence or absence of rejection, no significant differences were found other than a slight elevation at the 6-month checkup (P = .03) but without clinical relevance, because the CA125 value was slightly higher in biopsy results without rejection. CONCLUSION The rapid reduction of CA125 corroborates its usefulness as a marker of congestion in heart failure. This biomarker is not useful for predicting rejection. However, in cases of very severe rejections that occurred with systemic congestion, it could be raised. It would be necessary to corroborate this hypothesis in a larger study with a higher number of severe rejections. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Full Text from ScienceDirect